Celebrating 10 Years of AACI’s CRI Meeting

CRI 2018 program coverOver on Twitter, we’ve been sharing facts and figures (plus a few snapshots) that showcase our annual Clinical Research Initiative Meeting through the years. From 83 attendees in 2009 to almost 400 this year, the meeting has seen rapid growth. 

As we gear up for this year’s meeting, let’s take a trip down memory lane…

  • Since 2009, AACI’s CRI has had four steering committee chairs: Dr. James Thomas (Medical College of Wisconsin Cancer Center), Dr. Tony Reid (UC San Diego Moores Cancer Center), Dr. Paul Martin (Fred Hutchinson Cancer Research Center) and Dr. Carrie Lee (UNC Lineberger Comprehensive Cancer Center). Fun fact: Dr. Thomas is the only attendee who has registered for all 10 meetings! 
  • In 2011, 18 abstracts were submitted to the meeting. In 2018, that number has grown to 68. Check out this year’s abstracts.
  • The CRI Listserv gives AACI’s 98 member centers a platform to share resources & crowdsource best practices. The Listserv had 330 subscribers in 2012. Today, that number has grown to 637.
  • Last year’s program theme was “Moving Science Forward.” This year’s CRI meeting is all about “Leveraging Change to Advance Cures for Cancer Patients.”
  • Over 60 posters will be on display at this year’s meeting. Members can join us for a poster session from 6:00-6:30 pm on Wednesday, July 11. Posters 2015
  • To follow along with the sessions and share your own thoughts (and photos!), use the hashtag #CRI2018 throughout the meeting (July 11-12, Loews Chicago O’Hare Hotel) and stay tuned for the rest of our #10yearsofCRI tweets today and tomorrow.
    Print
Advertisements

Three New Members Join AACI CRI Steering Committee

AACI congratulates the following new members of the AACI Clinical Research Initiative (CRI) Steering Committee. Each will serve a three-year term beginning September 1, 2015:

  • Rosemarie Gagliardi, Tisch Cancer Institute, Mount Sinai Medical Center
  • Jessica Moehle, BS, CCRP, Huntsman Cancer Institute, University of Utah
  • Steve Williamson, MD, University of Kansas Cancer Center
New CRI Steering Committee members (L-R) Gagliari, Moehle and Williamson.

New CRI Steering Committee Members (L-R) Gagliardi, Moehle and Williamson.

The AACI CRI is a network of cancer center clinical research leaders that examines and shares best practices that promote the efficient operation of cancer center clinical research facilities, and leverages the ability of the AACI cancer center network to advocate for improvement in the national clinical trials enterprise.

Rosemarie Gagliardi is Associate Dean of Research Services, Icahn School of Medicine at Mount Sinai;  Operations Director, Cancer Clinical Trials Office (CCTO), Tisch Cancer Institute; and Assistant Professor, Department of Population Health Science and Policy. The primary mission of the Tisch Cancer Institute Clinical Protocol and Data Monitoring (CPDM) program is to assist investigators in the development, conduct, and reporting of clinical research in an efficient, compliant and scientifically sound manner. The CPDM provides regulatory, budgeting, study management, compliance, data management and reporting services to ensure clinical research uniformity and consistency. Ms. Gagliardi serves as the CCTO Operations Director, a role established in 2011 to provide direct management of CPDM operations.

Jessica Moehle is Associate Director of Operations, Clinical Trials Office, at Huntsman Cancer Institute. She has more than ten years of clinical research experience, including directing operations for the clinical trials office overseeing a staff of 109 FTEs. Prior to this time she served as the Clinical Trials Regulatory Department Manager and specialized in project management, operational leadership, protocol development, clinical trial portfolio management, IRB regulation, IND submissions, FDA regulation, NCI National Reporting criteria, principal investigator and pharmaceutical sponsor relations, clinical trial staff hiring and training. Ms. Moehle also spent several years in pre-clinical office administration at the National Institutes of Health, Division of AIDS, and Vaccine Research Program.

Stephen Williamson is Medical Director, Clinical Trials Research Unit, and Phase I Director, at University of Kansas Cancer Center. He has been involved in clinical trials research since his oncology fellowship, starting in 1984. Dr. Williamson has been involved in clinical trial development locally and nationally through the Southwest Oncology Group (now known as SWOG). Since 1986 he has been active in the Lung, GI and Head and Neck Committees of the Southwest Oncology Group. His first multi-institutional phase II trial through SWOG was initiated in 1986 and he has been the principal investigator on multiple investigator-initiated trials at the University of Kansas, including a phase I gene therapy clinical trial utilizing irradiated autologous melanoma cells adenovirally transduced with the human GM-CSF gene.